Rachel L Denlinger-Apte1, Cassidy M White2, Eric C Donny3, Dorothy K Hatsukami4, Neal L Benowitz5, Matthew J Carpenter6, Tracy T Smith7. 1. Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: rdenling@wakehealth.edu. 2. Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: cawhite@wakeahealth.edu. 3. Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. 4. Department of Psychiatry and Behavioral Sciences and Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55414, USA. Electronic address: hatsu001@umn.edu. 5. Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA. Electronic address: neal.benowitz@ucsf.edu. 6. Department of Psychiatry and Behavioral Sciences and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. Electronic address: carpente@musc.edu. 7. Department of Psychiatry and Behavioral Sciences and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. Electronic address: smithtra@musc.edu.
Abstract
BACKGROUND: The U.S. Food and Drug Administration (FDA) is considering a low-nicotine product standard for cigarettes. The purpose of this qualitative study was to explore participants' experiences after 72 hours of exclusively smoking very low nicotine content (VLNC) cigarettes. METHODS: We conducted a residential study during which participants who smoked cigarettes (N = 16) stayed in a smoking-friendly hotel for 5 days/4 nights. Participants only had access to VLNC cigarettes and were told the cigarettes had 97% less nicotine compared to conventional cigarettes. We conducted individual interviews with participants to assess their initial expectations about VLNC cigarettes, subjective experiences when smoking VLNC cigarettes, opinions regarding a low-nicotine product standard, and predicted use behavior if only VLNC cigarettes were available. Interviews were transcribed verbatim and analyzed using thematic analysis methods. RESULTS: Several participants expected, prior to trying VLNC cigarettes, to compensate for the reduced nicotine levels by smoking more cigarettes but were surprised when they did not increase their smoking. A subset of participants reported experiencing minor withdrawal symptoms, such as irritability and fatigue. Several participants reported feeling less dependent after exclusively smoking VLNC cigarettes. Most participants said they would smoke VLNC cigarettes if they were the only cigarettes available to purchase. Some also said that smoking VLNC cigarettes could help people taper down or quit smoking. CONCLUSIONS: Health communication strategies are needed to inform people who smoke about what to expect from a low-nicotine product standard for cigarettes in order to maximize the public health impact of the policy and increase support.
BACKGROUND: The U.S. Food and Drug Administration (FDA) is considering a low-nicotine product standard for cigarettes. The purpose of this qualitative study was to explore participants' experiences after 72 hours of exclusively smoking very low nicotine content (VLNC) cigarettes. METHODS: We conducted a residential study during which participants who smoked cigarettes (N = 16) stayed in a smoking-friendly hotel for 5 days/4 nights. Participants only had access to VLNC cigarettes and were told the cigarettes had 97% less nicotine compared to conventional cigarettes. We conducted individual interviews with participants to assess their initial expectations about VLNC cigarettes, subjective experiences when smoking VLNC cigarettes, opinions regarding a low-nicotine product standard, and predicted use behavior if only VLNC cigarettes were available. Interviews were transcribed verbatim and analyzed using thematic analysis methods. RESULTS: Several participants expected, prior to trying VLNC cigarettes, to compensate for the reduced nicotine levels by smoking more cigarettes but were surprised when they did not increase their smoking. A subset of participants reported experiencing minor withdrawal symptoms, such as irritability and fatigue. Several participants reported feeling less dependent after exclusively smoking VLNC cigarettes. Most participants said they would smoke VLNC cigarettes if they were the only cigarettes available to purchase. Some also said that smoking VLNC cigarettes could help people taper down or quit smoking. CONCLUSIONS: Health communication strategies are needed to inform people who smoke about what to expect from a low-nicotine product standard for cigarettes in order to maximize the public health impact of the policy and increase support.
Authors: Eric C Donny; Rachel L Denlinger; Jennifer W Tidey; Joseph S Koopmeiners; Neal L Benowitz; Ryan G Vandrey; Mustafa al'Absi; Steven G Carmella; Paul M Cinciripini; Sarah S Dermody; David J Drobes; Stephen S Hecht; Joni Jensen; Tonya Lane; Chap T Le; F Joseph McClernon; Ivan D Montoya; Sharon E Murphy; Jason D Robinson; Maxine L Stitzer; Andrew A Strasser; Hilary Tindle; Dorothy K Hatsukami Journal: N Engl J Med Date: 2015-10 Impact factor: 91.245
Authors: Kurt M Ribisl; Dorothy K Hatsukami; Jidong Huang; Rebecca S Williams; Eric C Donny Journal: Am J Public Health Date: 2019-07 Impact factor: 9.308
Authors: Sarah S Dermody; F Joseph McClernon; Neal Benowitz; Xianghua Luo; Jennifer W Tidey; Tracy T Smith; Ryan Vandrey; Dorothy Hatsukami; Eric C Donny Journal: Exp Clin Psychopharmacol Date: 2018-03-05 Impact factor: 3.157
Authors: Tracy T Smith; Joseph S Koopmeiners; Katelyn M Tessier; Esa M Davis; Cynthia A Conklin; Rachel L Denlinger-Apte; Tonya Lane; Sharon E Murphy; Jennifer W Tidey; Dorothy K Hatsukami; Eric C Donny Journal: Am J Prev Med Date: 2019-10 Impact factor: 5.043
Authors: Rachel L Denlinger-Apte; Jennifer W Tidey; Joseph S Koopmeiners; Dorothy K Hatsukami; Tracy T Smith; Lauren R Pacek; F Joseph McClernon; Eric C Donny Journal: Tob Control Date: 2018-11-01 Impact factor: 7.552
Authors: Rachel L Denlinger; Tracy T Smith; Sharon E Murphy; Joseph S Koopmeiners; Neal L Benowitz; Dorothy K Hatsukami; Lauren R Pacek; Cirielle Colino; Samantha N Cwalina; Eric C Donny Journal: Tob Regul Sci Date: 2016-04
Authors: Jennifer W Tidey; Suzanne M Colby; Rachel L Denlinger-Apte; Christine Goodwin; Patricia A Cioe; Rachel N Cassidy; Robert M Swift; Bruce R Lindgren; Nathan Rubin; Sharon E Murphy; Stephen S Hecht; Dorothy K Hatsukami; Eric C Donny Journal: Nicotine Tob Res Date: 2019-12-23 Impact factor: 4.244
Authors: Rachel L Denlinger-Apte; Michael Kotlyar; Joseph S Koopmeiners; Jennifer W Tidey; Xianghua Luo; Neal L Benowitz; Joni A Jensen; Joshua O Ikuemonisan; Lauren R Pacek; Tracy T Smith; Ryan Vandrey; Eric C Donny; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2019-12-23 Impact factor: 4.244
Authors: Katherine C Henderson; Emily E Loud; Hue Trong Duong; Reed M Reynolds; Bo Yang; Charity A Ntansah; David L Ashley; James F Thrasher; Lucy Popova Journal: Nicotine Tob Res Date: 2022-08-06 Impact factor: 5.825
Authors: Hue Trong Duong; Emily E Loud; James F Thrasher; Katherine C Henderson; David L Ashley; Lucy Popova Journal: Tob Control Date: 2021-04-16 Impact factor: 6.953
Authors: Amanda M Palmer; Benjamin A Toll; Matthew J Carpenter; Eric C Donny; Dorothy K Hatsukami; Alana M Rojewski; Tracy T Smith; Mehmet Sofuoglu; Johannes Thrul; Neal L Benowitz Journal: Nicotine Tob Res Date: 2022-01-01 Impact factor: 5.825